Percent with a Fragility Fracture Filling Prescription for an Osteoporosis Drug within Six Months
  • Print
  • PDF
  • Embed

    Copy the following code and paste it into your website in order to display the current report.

  • Download to Excel

Customize Report

    • YEAR:

    Choose Locations

    [clear all] [select all] Selected Locations:

      Choose Indicator(s)

      Select one or more indicators
      • TOPIC:
      • INDICATOR:
      • YEAR:

      [clear all] Selected Indicators:


    (Click a region name
    below to view its profile)
    Percent with a Fragility Fracture Filling Prescription for an Osteoporosis Drug within Six Months
    (Year: 2006-2010; Region Levels: State)
    Alabama 15.4%
    Alaska na
    Arizona 14.2%
    Arkansas 13.8%
    California 16.6%
    Colorado 17.3%
    Connecticut 12.0%
    Delaware 13.3%
    District of Columbia na
    Florida 14.4%
    Georgia 13.8%
    Hawaii 28.0%
    Idaho 9.9%
    Illinois 13.6%
    Indiana 16.9%
    Iowa 14.6%
    Kansas 15.8%
    Kentucky 12.7%
    Louisiana 15.4%
    Maine 10.7%
    Maryland 13.3%
    Massachusetts 13.2%
    Michigan 13.3%
    Minnesota 12.3%
    Mississippi 13.8%
    Missouri 14.0%
    Montana 17.3%
    Nebraska 13.4%
    Nevada 16.4%
    New Hampshire 12.1%
    New Jersey 10.9%
    New Mexico 15.8%
    New York 15.0%
    North Carolina 13.8%
    North Dakota 14.6%
    Ohio 14.4%
    Oklahoma 16.0%
    Oregon 15.2%
    Pennsylvania 13.6%
    Rhode Island 12.7%
    South Carolina 15.1%
    South Dakota 13.5%
    Tennessee 14.9%
    Texas 15.3%
    Utah 13.0%
    Vermont 11.7%
    Virginia 11.9%
    Washington 14.1%
    West Virginia 12.8%
    Wisconsin 13.6%
    Wyoming 13.8%
    National Average 14.3%
    90th Percentile 16.6%
    50th Percentile 13.8%
    10th Percentile 11.9%
        • Patients were included in the fragility fracture cohort if they (1) experienced a fracture of the hip, distal forearm or humerus between 5/1/2006 and 12/31/2009, (2) were continuously enrolled in fee-for-service Medicare Parts A and B for at least 36 months preceding the index fracture and at least 12 months following the fracture, (3) were alive and continuously enrolled in and used (one or more fill record) a stand-alone Medicare Part D plan for at least 6 months following the fracture, (4) did not have an identically-defined fragility fracture in the 36 months preceding the index fracture, (5) were predominantly community dwelling (not hospitalized for more than 90 days and had no prescriptions filled by a long-term care pharmacy type) in the first 6 months following index fracture, (6) had no cancer diagnosis (other than non-melanoma skin cancer), hospice enrollment, or managed Medicare enrollment at any time in claims records analyzed.

        • All medication use measures were based on Part D event fill records for the time frame specific to each cohort’s observation. The Lexi-Data Basic database (Lexicomp) was used to obtain the drug name, dose, brand or generic status, and active ingredient according to the National Drug Code (NDC).

    © 2018 Dartmouth Atlas of Health Care | 35 Centerra Parkway, Lebanon, NH 03766 | (603) 653-0800

    The Dartmouth Atlas of Health Care is based at The Dartmouth Institute for Health Policy and Clinical Practice and is supported by a coalition of funders led by the Robert Wood Johnson Foundation, including the WellPoint Foundation, the United Health Foundation, the California HealthCare Foundation, and the Charles H. Hood Foundation.

    The Dartmouth Institute for Health Policy & Clinical Practice Velir Datacenter Powered